{"date":"2026-06-02","count":18,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6949-2026-06-02-2026-rxlv1v","company_id":"6949","company":"沛爾生醫*-創","market":"上市","industry":"生技醫療","date":"2026-06-02","time":"20:26:16","subject":"代100%持有之子公司沛?(上海)醫藥科技有限公司公告，本公司研發針對類風濕關節炎(RA)之口服新藥PP011，接獲中國國家藥品監督管理局（NMPA）同意進行第一期健康受試者臨床試驗","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：沛爾生醫*-創（6949），2026-06-02 20:26，「代100%持有之子公司沛?(上海)醫藥科技有限公司公告，本公司研發針對類風濕關節炎(RA)之口服新藥PP011，接獲中國」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6696-2026-06-02-2003-1xt9dwk","company_id":"6696","company":"仁新*","market":"興櫃","industry":"生技醫療","date":"2026-06-02","time":"20:03:26","subject":"代重要子公司Belite Bio, Inc公告受邀參加高盛第47屆全球醫療論壇(Goldman Sachs 47th AnnualGlobal Healthcare Conference)","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：仁新*（6696），2026-06-02 20:03，「代重要子公司Belite Bio, Inc公告受邀參加高盛第47屆全球醫療論壇(Goldman Sachs 47th A」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4745-2026-06-02-1931-knykg8","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2026-06-02","time":"19:31:26","subject":"(補充115/05/28公告)本公司註銷買回庫藏股辦理完成-調整主管機關核准減資日期","clause":"","fact_date":"","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2026-06-02 19:31，「(補充115/05/28公告)本公司註銷買回庫藏股辦理完成-調整主管機關核准減資日期」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4109-2026-06-02-1733-1swbs7d","company_id":"4109","company":"加捷生醫","market":"上櫃","industry":"生技醫療","date":"2026-06-02","time":"17:33:47","subject":"公告本公司第二屆提名委員會委員","clause":"第6款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：加捷生醫（4109），2026-06-02 17:33，「公告本公司第二屆提名委員會委員」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4109-2026-06-02-1733-2utpcx","company_id":"4109","company":"加捷生醫","market":"上櫃","industry":"生技醫療","date":"2026-06-02","time":"17:33:27","subject":"公告本公司董事會決議通過委任第七屆薪酬委員會委員","clause":"第6款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：加捷生醫（4109），2026-06-02 17:33，「公告本公司董事會決議通過委任第七屆薪酬委員會委員」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4109-2026-06-02-1733-cwb10f","company_id":"4109","company":"加捷生醫","market":"上櫃","industry":"生技醫療","date":"2026-06-02","time":"17:33:12","subject":"公告本公司第二屆風險管理委員會委員","clause":"第6款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：加捷生醫（4109），2026-06-02 17:33，「公告本公司第二屆風險管理委員會委員」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4109-2026-06-02-1732-1nwix1l","company_id":"4109","company":"加捷生醫","market":"上櫃","industry":"生技醫療","date":"2026-06-02","time":"17:32:58","subject":"公告本公司第二屆永續發展委員會委員","clause":"第6款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：加捷生醫（4109），2026-06-02 17:32，「公告本公司第二屆永續發展委員會委員」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6808-2026-06-02-1708-b2kslx","company_id":"6808","company":"三鼎生技","market":"興櫃","industry":"生技醫療","date":"2026-06-02","time":"17:08:31","subject":"公告本公司總經理辭任","clause":"第6款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：三鼎生技（6808），2026-06-02 17:08，「公告本公司總經理辭任」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4726-2026-06-02-1707-snismb","company_id":"4726","company":"永昕","market":"上櫃","industry":"生技醫療","date":"2026-06-02","time":"17:07:59","subject":"本公司受邀參加國票證券法人說明會","clause":"第12款","fact_date":"2026-06-09","cite_as":"公開資訊觀測站重大訊息：永昕（4726），2026-06-02 17:07，「本公司受邀參加國票證券法人說明會」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-06-02-1706-1w3sln1","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-06-02","time":"17:06:08","subject":"本公司辦理現金減資致債權人公告","clause":"第51款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-06-02 17:06，「本公司辦理現金減資致債權人公告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4155-2026-06-02-1657-15e1v8f","company_id":"4155","company":"訊映","market":"上市","industry":"生技醫療","date":"2026-06-02","time":"16:57:10","subject":"本公司115年股東常會重要決議事項","clause":"第18款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：訊映（4155），2026-06-02 16:57，「本公司115年股東常會重要決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4736-2026-06-02-1647-vxh4e5","company_id":"4736","company":"泰博","market":"上市","industry":"生技醫療","date":"2026-06-02","time":"16:47:14","subject":"公告本公司處分有價證券","clause":"第20款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：泰博（4736），2026-06-02 16:47，「公告本公司處分有價證券」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7427-2026-06-02-1616-ny2w8u","company_id":"7427","company":"華上生醫","market":"興櫃","industry":"生技醫療","date":"2026-06-02","time":"16:16:46","subject":"公告本公司自主開發擁有全球開發權利的表觀遺傳免疫活化新藥GNTbm-38，遞交TFDA已獲受理臨床一期試驗的IND申請。","clause":"第8款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：華上生醫（7427），2026-06-02 16:16，「公告本公司自主開發擁有全球開發權利的表觀遺傳免疫活化新藥GNTbm-38，遞交TFDA已獲受理臨床一期試驗的IND申請。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7881-2026-06-02-1612-19b1djy","company_id":"7881","company":"科明","market":"興櫃","industry":"生技醫療","date":"2026-06-02","time":"16:12:41","subject":"公告本公司配合會計師事務所內部輪調變更會計師","clause":"第7款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：科明（7881），2026-06-02 16:12，「公告本公司配合會計師事務所內部輪調變更會計師」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7881-2026-06-02-1610-ivopaw","company_id":"7881","company":"科明","market":"興櫃","industry":"生技醫療","date":"2026-06-02","time":"16:10:50","subject":"公告本公司董事會通過115年度第一季合併財務報表","clause":"第43款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：科明（7881），2026-06-02 16:10，「公告本公司董事會通過115年度第一季合併財務報表」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7881-2026-06-02-1607-80m8yy","company_id":"7881","company":"科明","market":"興櫃","industry":"生技醫療","date":"2026-06-02","time":"16:07:42","subject":"公告本公司董事會通過新設置公司治理主管任命案","clause":"第11款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：科明（7881），2026-06-02 16:07，「公告本公司董事會通過新設置公司治理主管任命案」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6945-2026-06-02-1545-ahexl4","company_id":"6945","company":"圓祥生技","market":"上櫃","industry":"生技醫療","date":"2026-06-02","time":"15:45:45","subject":"公告本公司股票初次上櫃前現金增資員工認購股款催繳事宜","clause":"第44款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：圓祥生技（6945），2026-06-02 15:45，「公告本公司股票初次上櫃前現金增資員工認購股款催繳事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6492-2026-06-02-1435-1iz8ta0","company_id":"6492","company":"生華科","market":"上櫃","industry":"生技醫療","date":"2026-06-02","time":"14:35:05","subject":"生華科新藥CX-5461首次聯合BeOne Medicines(百濟神州)已上市免疫檢查點抑制劑Tislelizumab治療多項晚期或轉移性實體腫瘤人體臨床試驗IND申請已獲美國FDA核准執行。","clause":"第53款","fact_date":"2026-06-02","cite_as":"公開資訊觀測站重大訊息：生華科（6492），2026-06-02 14:35，「生華科新藥CX-5461首次聯合BeOne Medicines(百濟神州)已上市免疫檢查點抑制劑Tislelizumab」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}